USA flag logo/image

An Official Website of the United States Government

Discovery of FN3K Inhibitors to Treat Diabetic Complications

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96051
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK088407
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
DYNAMIS THERAPEUTICS, INC.
261 OLD YORK RD, SUITE 427 JENKINTOWN, PA 19046
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Discovery of FN3K Inhibitors to Treat Diabetic Complications
Agency: HHS
Contract: 1R43DK088407-01A1
Award Amount: $257,579.00
 

Abstract:

DESCRIPTION (provided by applicant): The glucose metabolite 3-deoxyglucosone (3DG) is a highly reactive, dicarbonyl, proinflammatory molecule that induces oxidative stress and is a precursor to the formation of advanced glycation end products (AGEs), which are believed to be important in mechanisms that directly contribute to the development of diabetic complications. Recent work indicates that 3DG levels are elevated in diabetics, and higher levels appear associated with more extensive retinopathy and neur opathy. The enzyme fructosamine-3-kinase (FN3K) produces 3DG, and our hypothesis is that the most direct way to lower 3DG is to inhibit this enzyme with a drug. This research will use high throughput screening (HTS) to find FN3K inhibitors that can be deve loped into drugs to treat people suffering from the debilitating complications of type II and type I diabetes. The HTS assay will use a novel, homogeneous method that measures the FN3K substrate-dependent enzymatic formation of ADP from ATP by a competitiv e immunoassay. To demonstrate that our HTS assay can reliably detect FN3K inhibitors, our SA1 objectives are to screen a 10,000 compound diversity subset of 'drug-like' small molecules. We will determine the potency (IC50) and selectivity values for any HT S 'hits'. Once we establish that the assay conditions are validated for HTS, the SA2 objective is to screen up to 100,000 diverse compounds, remove non-specific and cytotoxic inhibitors and assess the functional activity of selective inhibitors in cells ov er-expressing FN3K. Our project goal is to discover drug lead candidates amenable to optimization with medicinal chemistry and suitable for preclinical testing. Developing and validating an automated HTS assay to detect FN3K inhibitors in large, diverse, d rug-like compound libraries is an important step to finding new tools to probe the physiological role of FN3K in health and disease, which will lead to new therapies to treat the complications of both Type I and II diabetes. PUBLIC HEALTH RELEVANCE: The enzyme FN3K produces the toxic compound 3-deoxyglucosone (3DG), a highly reactive molecule that leads to the formation of advanced glycation end products (AGEs), which contribute to diabetic complications. This research will test compounds by HTS with an appropriate biochemical screen and perform appropriate follow-up assays to identify FN3K inhibitors that can be developed into drugs to treat people suffering from the debilitating complications of type II and type I diabetes.

Principal Investigator:

Alice Marcy
2157801482
AIMARC23@AOL.COM

Business Contact:

Kevin Kimmel
amarcy@dynamis-therapeutics.com
Small Business Information at Submission:

DYNAMIS THERAPEUTICS, INC.
DYNAMIS THERAPEUTICS, INC. 261 OLD YORK RD, SUITE 427 JENKINTOWN, PA 19046

EIN/Tax ID: 123290934
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No